The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC
Videos  >  

Determining Resistance to a Taxane or Anthracyclines in Breast Cancer

Linda D. Bosserman, MD, FACP
Published Online:9:50 PM, Tue August 12, 2014
Linda D. Bosserman, MD, FACP, president, medical oncologist, Wilshire Oncology Medical Group, discusses how she determines if a patient is resistant to a taxane or anthracyclines.

This segment is a part of our Case-Based Peer Perspectives. View the case details > >
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.